Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 1
2008 3
2018 1
2021 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

6 results

Results by year

Filters applied: . Clear all
Page 1
Diabetic trigger finger.
Benedetti A, Noacco C, Simonutti M, Taboga C. Benedetti A, et al. N Engl J Med. 1982 Jun 24;306(25):1552. doi: 10.1056/nejm198206243062516. N Engl J Med. 1982. PMID: 7078615 No abstract available.
Efficacy and tolerability of rosuvastatin and atorvastatin when force-titrated in patients with primary hypercholesterolemia: results from the ECLIPSE study.
Faergeman O, Hill L, Windler E, Wiklund O, Asmar R, Duffield E, Sosef F; ECLIPSE Study Investigators. Faergeman O, et al. Cardiology. 2008;111(4):219-28. doi: 10.1159/000127442. Epub 2008 Apr 23. Cardiology. 2008. PMID: 18434729 Clinical Trial.
METHODS: In this 24-week, open-label, randomized, multinational, parallel-group study, 1,036 patients were randomized to rosuvastatin (n = 522) or atorvastatin (n = 514). RESULTS: At all time points, a significantly greater percentage of patients on rosuvastatin tre …
METHODS: In this 24-week, open-label, randomized, multinational, parallel-group study, 1,036 patients were randomized to rosuvastatin (n …
Simple colorimetric method to determine the in vitro antioxidant activity of different monoterpenes.
Noacco N, Rodenak-Kladniew B, de Bravo MG, Castro GR, Islan GA. Noacco N, et al. Anal Biochem. 2018 Aug 15;555:59-66. doi: 10.1016/j.ab.2018.06.007. Epub 2018 Jun 15. Anal Biochem. 2018. PMID: 29908862
Natural antioxidants like vitamins C and E, resveratrol, dithiothreitol, N-actyl-l-cysteine and glutathione were used as controls to validate the assay. ...
Natural antioxidants like vitamins C and E, resveratrol, dithiothreitol, N-actyl-l-cysteine and glutathione were used as controls to …
Design of magnetic hybrid nanostructured lipid carriers containing 1,8-cineole as delivery systems for anticancer drugs: Physicochemical and cytotoxic studies.
Rodenak-Kladniew B, Noacco N, Pérez de Berti I, Stewart SJ, Cabrera AF, Alvarez VA, García de Bravo M, Durán N, Castro GR, Islan GA. Rodenak-Kladniew B, et al. Colloids Surf B Biointerfaces. 2021 Jun;202:111710. doi: 10.1016/j.colsurfb.2021.111710. Epub 2021 Mar 19. Colloids Surf B Biointerfaces. 2021. PMID: 33765626
Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials.
Chaturvedi N, Porta M, Klein R, Orchard T, Fuller J, Parving HH, Bilous R, Sjølie AK; DIRECT Programme Study Group. Chaturvedi N, et al. Lancet. 2008 Oct 18;372(9647):1394-402. doi: 10.1016/S0140-6736(08)61412-9. Epub 2008 Sep 25. Lancet. 2008. PMID: 18823656 Clinical Trial.
FINDINGS: 1421 participants (aged 18-50 years) were randomly assigned to candesartan (n=711) or to placebo (n=710) in DIRECT-Prevent 1, and 1905 (aged 18-55 years) to candesartan (n=951) or to placebo (n=954) in DIRECT-Protect 1. ...
FINDINGS: 1421 participants (aged 18-50 years) were randomly assigned to candesartan (n=711) or to placebo (n=710) in DIRECT-P …
Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial.
Sjølie AK, Klein R, Porta M, Orchard T, Fuller J, Parving HH, Bilous R, Chaturvedi N; DIRECT Programme Study Group. Sjølie AK, et al. Lancet. 2008 Oct 18;372(9647):1385-93. doi: 10.1016/S0140-6736(08)61411-7. Epub 2008 Sep 25. Lancet. 2008. PMID: 18823658 Free article. Clinical Trial.
FINDINGS: 1905 participants (aged 37-75 years) were randomised to candesartan (n=951) or placebo (n=954). 161 (17%) patients in the candesartan group and 182 (19%) in the placebo group had progression of retinopathy by three steps or more on the Early Treatment Diab …
FINDINGS: 1905 participants (aged 37-75 years) were randomised to candesartan (n=951) or placebo (n=954). 161 (17%) patients i …